Request More Information

Change: Change(%):
Volume: Open:
High: Low:
52Wk High: 52Wk Low:

Experts Commenting on This Company


Visit Company Website

View Company News

BELLUS Health Inc.


BELLUS Health Inc. is a drug development company focused on rare diseases. Based in Laval, Quebec, the company has a portfolio of rare disease projects including KIACTA for AA amyloidosis (an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death), clinical-stage Shigamab for Shiga toxin-producing Escherichia coli-related hemolytic uremic syndrome, and a research-stage project for AL amyloidosis. Its lead program, KIACTA, is partnered with global private equity firm Auven Therapeutics LLLP and is currently in phase 3 confirmation study.

The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.

Expert Comments:

The Life Sciences Report Interview with Hugh Cleland (3/19/14) "BELLUS Health Inc. presented to our advisory board back in May 2013 and came out as one of the favorites. . .one thing that really grabbed me was the enormous valuation disparity that has existed for a variety of very unusual circumstances. With BELLUS, you have a fully funded orphan drug candidate called Kiacta (eprodisate disodium, an orally available small molecule) that is in a phase 3 trial reasonably close to the end of enrollment. The drug is being tested in a lethal disease called AA amyloidosis, which affects 50,000 people in the U.S., Europe and Japan.

The company indicates expected peak sales of around US$500M, but our research suggests we could see peak sales significantly higher than that, perhaps as high as US$1B. Yet somehow, the company is still trading at a fully diluted enterprise value of less than US$35M. I have never seen a fully funded phase 3 asset with such a big market opportunity trade at such a ludicrously low valuation." More >

Pooya Hemami, Edison Investment Research (1/7/14) "BELLUS Health Inc. has announced that it now expects the event-driven phase 3 study for Kiacta in AA amyloidosis to be completed in 2016, earlier than the previously anticipated target of 2017. A reduction in the time to study data, and potentially for Kiacta to reach the market, is a positive development and we raise our risk-adjusted NPV valuation to CA$40M (versus CA$26M), or CA$0.87/share (including cash, fully diluted)."

Pooya Hemami, Edison Investment Research (11/8/13) "BELLUS Health Inc. has divested its Vivimind and BLU8499 noncore assets in order to strengthen its focus on its orphan disease drug candidates, Kiacta and Shigamabs. . .the company is fully funded until the Kiacta study results. . .we continue to estimate a 60% probability of Kiacta's success based on an expected 2018 commercial launch in AA amyloidosis."

Due to permission requirements, not all quotes are shown.

BELLUS Health Inc. Content

Back to Top

Would you like additional information on Biotechnology/Pharmaceuticals companies?